Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer

被引:21
|
作者
Cruz-Rico, Graciela [1 ]
Aviles-Salas, Alejandro [3 ]
Segura-Gonzalez, Manuel [2 ]
Maria Espinosa-Garcia, Ana [4 ]
Alejandra Ramirez-Tirado, Laura [1 ]
Morales-Oyarvide, Vicente [2 ]
Rojas-Marin, Carlos [3 ]
Cardona, Andres-Felipe [5 ]
Arrieta, Oscar [1 ,2 ]
机构
[1] Hosp Gen Mexico City, Expt Oncol Lab, Mexico City, DF, Mexico
[2] Hosp Gen Mexico City, Clin Thorac Oncol, Mexico City, DF, Mexico
[3] Hosp Gen Mexico City, Inst Nacl Cancerol INCan, Dept Pathol, Mexico City, DF, Mexico
[4] Hosp Gen Mexico City, Gen Med Lab, Mexico City, DF, Mexico
[5] Clin Cty, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia
关键词
non-small cell lung carcinoma; anaplastic lymphoma kinase; routine diagnostic tests; immunohistochemistry; real-time polymerase chain reaction; ANAPLASTIC LYMPHOMA; FUSION GENE; ALK REARRANGEMENT; KINASE; ADENOCARCINOMA; CRIZOTINIB; INHIBITOR; FEATURES; IDENTIFICATION; CHEMOTHERAPY;
D O I
10.1097/COC.0000000000000213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess anaplastic lymphoma kinase (ALK) rearrangement detection with immunohistochemistry (IHC) and real-time polymerase chain reaction (RT-qPCR) in comparison with fluorescence in situ hybridization (FISH). Methods: Tumor tissue samples from 230 patients with advanced non-small cell lung cancer (NSCLC) were analyzed by FISH to detect ALK rearrangements. Additional IHC tests using 5A4 clone and RT-qPCR (variants 1 to 5) were performed in 63 and 48 patients, respectively. Results: Thirteen percent of FISH tests were not evaluable. From the remaining tests (n = 200), 18 (9.0%) were ALK positive (ALK(+)). ALK(+) patients were significantly younger at the time of diagnosis (below 55 y, 14.3% vs. 5.5%, P = 0.035), were light smokers (tobacco index < 10, 12.6% vs. 4.1%, P = 0.049), and presented adenocarcinoma with a mucinous component (30.8 vs. 8.0%, P = 0.007). When comparing FISH with IHC using a cutoff of 1 + or 2 +, and only 2 + staining intensity, the sensitivity, specificity, negative predictive value, and positive predictive value were as follows: 83.3%, 100.0%, 93.75%, and 100.0%; and 55.6%, 100.0%, 84.9%, and 100.0%, respectively. For RT-qPCR, these results were 55.6, 100, 90.7, and 100.0%, respectively. Conclusions: Our results suggest that RT-qPCR is an inadequate initial test for detecting ALK-positive lung cancer. IHC is highly useful as an initial screening test for ALK rearrangement detection in NSCLC. These results contribute to the medical literature on the establishment of IHC as a standard diagnostic test for ALK rearrangements in NSCLC.
引用
收藏
页码:631 / 638
页数:8
相关论文
共 50 条
  • [41] Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation
    Perez, Cesar A.
    Velez, Michel
    Raez, Luis E.
    Santos, Edgardo S.
    LUNG CANCER, 2014, 84 (02) : 110 - 115
  • [42] Detection of EML4-ALK Fusion Gene in Chinese Non-Small Cell Lung Cancer by Using a Sensitive Quantitative Real-Time Reverse Transcriptase PCR Technique
    Fu, Sha
    Wang, Fang
    Shao, Qiong
    Zhang, Xu
    Duan, Li-Ping
    Zhang, Xiao
    Zhang, Li
    Shao, Jian-Yong
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (04) : 245 - 254
  • [43] EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
    Gower, Arjan
    Hsu, Wei-Hsun
    Hsu, Shuo-Tse
    Wang, Yisong
    Giaccone, Giuseppe
    MOLECULAR ONCOLOGY, 2016, 10 (04) : 601 - 609
  • [44] EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries
    Elshatlawy, Mariam
    Sampson, Josephina
    Clarke, Katy
    Bayliss, Richard
    MOLECULAR ONCOLOGY, 2023, 17 (06) : 950 - 963
  • [45] EML4-ALK fusion transcripts identification in circulating blood platelets and exosomes in non-small cell lung cancer patients
    Sanchez-Herrero, E.
    Barquin, M.
    Perez-Barrios, C.
    Ortiz, N.
    Sanz, S.
    Rodriguez, A.
    Auglyte, M.
    Garcia-Campelo, R.
    Sanchez, J. M.
    Provencio, M.
    Romero, A.
    CLINICA CHIMICA ACTA, 2019, 493 : S158 - S158
  • [46] Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer
    Zou, Zihua
    Wu, Lige
    Hao, Xuezhi
    Li, Yan
    Liang, Li
    Gu, Yangchun
    Ying, Jianming
    Li, Junling
    Xing, Puyuan
    THORACIC CANCER, 2025, 16 (02)
  • [47] A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer
    Soda, Manabu
    Isobe, Kazutoshi
    Inoue, Akira
    Maemondo, Makoto
    Oizumi, Satoshi
    Fujita, Yuka
    Gemma, Akihiko
    Yamashita, Yoshihiro
    Ueno, Toshihide
    Takeuchi, Kengo
    Choi, Young Lim
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Hagiwara, Koichi
    Mano, Hiroyuki
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5682 - 5689
  • [48] EML4-ALK Fusion Subtype Is Associated with Therapeutic Efficacy in Advanced Non-Small Cell Lung Cancer
    Wang, H.
    Li, H.
    Ma, J.
    Yan, X.
    Li, P.
    Zhang, M.
    Zhang, X.
    Zhang, G.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S847 - S847
  • [49] Correlation Analysis of EML4-ALK Fusion Gene Mutation and Clinical Features in Patients With Non-small Cell Lung Cancer
    Han Zhen
    Zhang Ying
    CHEST, 2016, 149 (04) : 277A - 277A
  • [50] EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas
    Shinmura, Kazuya
    Kageyama, Shinji
    Igarashi, Hisaki
    Kamo, Takaharu
    Mochizuki, Takahiro
    Suzuki, Kazuya
    Tanahashi, Masayuki
    Niwa, Hiroshi
    Ogawa, Hiroshi
    Sugimura, Haruhiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (02) : 271 - 275